HIV PrEP options:
Truvada (Tenofovir Disoproxil Fumarate/Emtricitabine [TDF-FTC]) - well tolerated; most studied regimen; can be used in all populations; can be administered as event-driven therapy for men who have sex with men and other persons who engage only in anal sex. However, event-driven dosing should be avoided in those with chronic HBV infection. Adverse effects: reduced kidney function, can result in bone loss; for patients with chronic HBV, they are at risk for flare of their liver disease if therapy is discontinued. TDF should not be used in persons with an eGFR <60. Patients require monitoring of creatinine on therapy.
Descovy (tenofovir alafenamide fumarate/Emtricitabine [TAF-FTC]) - Well tolerated; less bone and renal toxicity compared with TDF; Should only be administered as daily therapy. Higher rates of mild triglyceride elevations and weight gain compared with TDF-FTC; considered an alternative agent for those whose main risk for HIV is vaginal (frontal) sex or who inject drugs since there is less data compared with TDF-FTC. There is also limited data in adolescents. For patients with chronic HBV, they are at risk for flare of their liver disease if therapy is discontinued.
Apretude (Cabotegravir LA) - well tolerated; every other month dosing via clinic-administered IM injection. Clinical trials suggest greater efficacy compared with TDF-FTC (possibly related to improved adherence). May be used for patients with conditions that are associated with an increased risk of adverse events with TDF-FTC or TAF-FTC (eg, those with reduced kidney function, bone disease). Cabotegravir LA levels may be detectable for up to 6 months. Because these levels are not protective, an oral agent (TDF-FTC or TAF-FTC) or consistent condom use is needed for a period of time in those who discontinue injectable therapy but continue to engage in behaviors that put them at increased risk for HIV. Oral therapy is also needed if the patient needs to miss a dose of cabotegravir. Patients may be at risk of developing an integrase inhibitor-resistant strain of HIV if infection is acquired when cabotegravir levels are suboptimal (e.g., missed dose or discontinuation). If this occurs, future HIV treatment options may be limited. Required proximity to a center that administers cabotegravir LA. Injection site reactions (generally mild). For those who are concerned about side effects of cabotegravir, oral cabotegravir (30 mg once daily) can be administered for a 4-week lead-in period prior to initiating injections.
Yeztugo (lenacapavir) - dosed every 6 months via clinic-administered SC injection. Clinical trials suggest greater efficacy than TDF-FTC and TAF-FTC (possibly related to improved adherence). May be used for patients with conditions that are associated with an increased risk of adverse events with TDF-FTC or TAF-FTC (eg, those with reduced kidney function, bone disease). If person acquires HIV, first-line antiretroviral agents can still be used. Lenacapavir levels may be detectable for up to a year. Because these levels are not protective, an oral agent (TDF-FTC or TAF-FTC) or consistent condom use is needed for a period of time in those who discontinue injectable therapy but continue to engage in behaviors that put them at increased risk for HIV. Oral therapy is also needed if the patient needs to miss a dose of lenacapavir. Requires proximity to a center that administers lenacapavir. Injection site reactions are generally mild, but can lead to persistent nodules in a small percentage of patients. Certain drug-drug interactions may exist with moderate and strong cytochrome P450 3A inducers. Lenacapavir is also a moderate cytochrome P450 3A inhibitor, which may increase exposure to drugs metabolized by this enzyme. These interactions may persist for up to 9 months after the last lenacapavir injection.












